v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (34,334) $ (48,479)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 3,047 2,999
Stock-based compensation 5,282 9,146
Amortization of debt discount and accretion of debt issuance costs 551 1,028
Amortization of licensed right to use technology 204 205
Amortization of operating lease assets 398 367
Change in fair value of warrant liability (35) (237)
Change in fair value of derivative liability 1,395 (1,314)
Unrealized loss on marketable securities 60
Provision for inventory losses 672 177
Provision for bad debt 91
Foreign currency adjustments (119)
Loss on extinguishment of debt 165 2,447
Impairment of fixed assets 505
Loss on disposal of fixed assets 431 334
Paid in kind interest 1,762 696
Changes in:    
Inventory 1,110 (466)
Accounts receivable (468) (390)
Other current assets and prepaid expenses 683 1,048
Accounts payable 267 399
Accrued expenses 1,127 (6,358)
Operating lease liabilities (373) (385)
Net cash used in operating activities (18,144) (38,218)
Cash flows from investing activities:    
Purchase of marketable securities (4,053) (30,878)
Proceeds from sale of marketable securities 1,404 51,656
Security deposits made on operating leases 10
Purchase of property and equipment (1,025) (5,883)
Net cash (used in)/provided by investing activities (3,674) 14,905
Cash flows from financing activities:    
Proceeds from issuance of common stock through at the market offerings, net 8,135 2,151
Proceeds from the sale of common stock of NeuroNos 700 2,000
Proceeds from issuance of common stock and pre-funded warrants through securities purchase, net 4,500 18,858
Proceeds from issuance of common stock through exercise of warrants 2,869 365
Proceeds from issuance of common stock warrants 90
Proceeds from long term loan 14,000 11,324
Debt issuance costs (996)
Payment of loan (208) (18,052)
Net cash provided by financing activities 29,090 16,646
Effect of exchange rate changes on cash and cash equivalents 194 (45)
Increase/(decrease) in cash, cash equivalents and restricted cash 7,466 (6,712)
Cash, cash equivalents and restricted cash at beginning of year 4,896 11,608
Cash, cash equivalents and restricted cash at end of year 12,362 4,896
Supplemental disclosure of non-cash investing and financing activities:    
Debt discount 1,094 3,249
Derivative liability 775
Short term finance liability 457 693
Fixed assets recorded in accounts payable and accrued expenses 398 396
Right-of-use assets acquired under operating leases 139
Debt principal balance converted to equity 1,171
Interest paid 423 1,197
Income taxes paid